Achilles Therapeutics Shares Are Trading Lower After the Company Reported Q4 Financial Results. The Company Announced Interim Phase I/IIa Data on the Use of Clonal Neoantigen Reactive T Cells From the CHIRON Study in Advanced Unresectable or Metastatic Non-small Cell Lung Cancer and the THETIS Study in Recurrent or Metastatic Malignant Melanoma
Achilles Therapeutics公布第四季度财务业绩后，该公司股价走低。该公司公布了关于使用克隆新抗原反应性T细胞的I/IIa期中期数据，这些数据来自CHIRON在晚期不可切除或转移性非小细胞肺癌中的研究和针对复发性或转移性恶性黑色素瘤的THETIS研究